Carregant...
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms
The discovery of the Janus kinase (JAK)2 V617F mutation in patients with myeloproliferative neoplasms was a major milestone in understanding the biology of those disorders. Several groups simultaneously reported on the high incidence of this mutation in patients with myeloproliferative neoplasms: al...
Guardat en:
| Publicat a: | Expert Rev Anticancer Ther |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5176249/ https://ncbi.nlm.nih.gov/pubmed/19445582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/era.09.14 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|